Protalix Biotherapeutics, Inc. (PLX) to Present at the Oppenheimer 14th Annual Israeli Conference
5/8/2013 9:29:09 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Treats First Gaucher Patient in Phase I Study With PRX-112, an Orally-Administered Enzyme Treatment of Gaucher Disease
4/2/2013 11:39:12 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Signs $8.3 Million Deal With Pfizer Inc. (PFE) to Continue Managing Elelyso Trials
12/6/2012 7:14:17 AM
More...
|
Pfizer Inc. (PFE), Protalix Biotherapeutics, Inc. (PLX)'s Gaucher Drug Rejected by EU Regulator
6/22/2012 8:29:05 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Announces Closing of Public Offering and Exercise of Over-Allotment Option
2/22/2012 2:19:02 PM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease Network Symposium
1/26/2012 9:24:18 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) Announces Successful European GMP Audit
12/1/2011 12:16:22 PM
More...
|
Protalix Biotherapeutics, Inc. (PLX) to Present at the UBS Global Life Sciences Conference
9/13/2011 12:04:41 PM
More...
|
Protalix Biotherapeutics, Inc. (PLX) to Present at Four Upcoming Healthcare Conferences
5/12/2011 6:42:21 AM
More...
|
Protalix Biotherapeutics, Inc. (PLX) to Present at the Bio-Manguinhos International Symposium on Immunobiologicals in Brazil and the 2011 ILSI-Biomed Conference in Israel
4/27/2011 9:09:10 AM
More...
|